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Abstract
There is a new merging of health economics and nutrition disciplines to assess the impact of diet on health and disease prevention and to
characterise the health and economic aspects of speciﬁc changes in nutritional behaviour and nutrition recommendations. A rationale exists
for developing the ﬁeld of nutrition economics which could offer a better understanding of both nutrition, in the context of having a
signiﬁcant inﬂuence on health outcomes, and economics, in order to estimate the absolute and relative monetary impact of health
measures. For this purpose, an expert meeting assessed questions aimed at clarifying the scope and identifying the key issues that
should be taken into consideration in developing nutrition economics as a discipline that could potentially address important questions.
We propose a ﬁrst multidisciplinary outline for understanding the principles and particular characteristics of this emerging ﬁeld. We
summarise here the concepts and the observations of workshop participants and propose a basic setting for nutrition economics and
health outcomes research as a novel discipline to support nutrition, health economics and health policy development in an evidence
and health-beneﬁt-based manner.
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The important role of food and nutrition in public health is
being increasingly recognised as crucial for its potential
impact on health-related quality of life (HRQoL) and econ-
omics, both at the societal and individual levels. Increasing
epidemiological and scientiﬁc evidence demonstrates
clear links between food and health maintenance/disease
development
(1). In developing countries, morbidity and
mortality are directly related to protein and energy mal-
nutrition, while in many Western countries, health ofﬁcials
have begun to actively promote the consumption of
healthy foods while reducing the amount of energy in
the diet. In parallel, the food industry has proceeded to
*Corresponding author: I. Lenoir-Wijnkoop, email irene.lenoir@danone.com
Abbreviations: HRQoL, health-related quality of life; QALY, quality-adjusted life years; RCT, randomised controlled trial.
British Journal of Nutrition (2011), 105, 157–166 doi:10.1017/S0007114510003041
q The Authors 2010. The online version of this article is published within an Open Access environment subject to the conditions of the
Creative Commons Attribution-NonCommercial-ShareAlike licence ,http://creativecommons.org/licenses/by-nc-sa/2.5/ . . The written
permission of Cambridge University Press must be obtained for commercial re-use.
B
r
i
t
i
s
h
J
o
u
r
n
a
l
o
f
N
u
t
r
i
t
i
o
ntackle nutrition- and health-associated challenges in two
complementary ways: (i) by removing or replacing
unhealthy ingredients (based on both national and
international recommendations) such as trans lipids, salt
and added sugar; (ii) by incorporating healthy or health-
promoting ingredients and bio-active compounds in new
products, for example vitamins, n-3 fats, plant extracts,
ﬁbres, ﬂavonoids, probiotics and prebiotics. Scarcity
cannot be eliminated while health spending is presently
rising faster than GDP in most of the developed
countries
(2). The question of how to optimise the use of
scarce resources, and the linkage between nutrition,
health and welfare should be studied in a broader
and more scientiﬁc way. This should include aspects and
methodologies that compare nutrition-related costs and
health outcomes, in order to sustain value-based decisions
within systems providing health care. A favourable impact
of food on nutrition-related disorders and general health
status may have a positive impact on health care
expenditure, thus contributing to public health and the
sustainability of health systems in general. Meanwhile,
the joint development of a discipline like nutrition econ-
omics may help the policymakers to encourage individual
responsibility for a healthy lifestyle.
The context of nutrition economics
Over the last decades, the interest in evidence-based health
care has grown considerably. In about the same time
period, the economic evaluation of health care technol-
ogies has been instituted. The introduction and develop-
ment of this discipline was a response to the demands of
decision makers who, faced by the increasing pressure
on the health care budget, ask for information not only
on the efﬁcacy and costs but also on the cost-effectiveness
of healthcare treatments. The principles of economic
evaluation have now become well established. Such
evaluations analyse the costs, savings and health effects
of a health technology, as compared to an alternative
(constituting a part of what has been named as Health
Technology Assessment). Therefore, health economics is
as much about health outcomes as it is about money.
Until now, no systematic and speciﬁc approach has been
developed for the assessment of the impact of food pro-
ducts on health, and HRQoL in our society. A methodology
speciﬁcally suited to the area of nutrition is lacking, despite
a clear need and important requirement from policymakers
as well as a direct interest for consumers. According to
a recent World Bank report on health-enhancing foods:
‘Currently, cost-effectiveness of functional foods in redu-
cing disease burden and lost productivity is an important
research gap’
(3). In a similar manner, a report by the
European Commission states: ‘... there is virtually no
information on the cost-effectiveness of functional food,
i.e. it is unclear at what cost the expected health beneﬁts
come. Studies indicate that functional food may help
prevent diseases that currently impose a heavy drain on
health care budgets’
(4).
To fully appreciate the context of nutrition economics, it
is necessary to be aware of the speciﬁc characteristics of
food. Food is, in the ﬁrst place, the source of macro- and
micronutrients for humans. However, the complexity of
food and its interactions with multiple interdependent
genetic, physiological, metabolic and psychological pro-
cesses that have an impact on human physical functioning
and psycho-social well-being requires a holistic approach,
different from the pharmaceutical ﬁeld, typically targeted
to speciﬁc functions. Food products have to be distin-
guished from classical pharmacological treatments. To
assess the health and economic impact of food products
and nutrition, it is not sufﬁcient to apply the methods of
pharmacoeconomics without modiﬁcations. Pharmaco-
economics was initially developed to allow health
authorities to decide on an efﬁcient allocation of available
resources between alternative strategies or treatments
(pharmaceuticals) and as an aid for decisions in health
care priority setting. Other features that limit a straightfor-
ward use of pharmacoeconomic models in the area of
nutrition include: (i) differences in the evaluation of risk
between pharmaceuticals and food products – in clinical
drug evaluations, risks to some patients are traded-off
against beneﬁts to the group, whereas in food regulation,
known risks are, in principle, not acceptable; (ii) preven-
tion and risk reduction v. treatment also challenge the
economical assessment – food is for everybody, whether
healthy or diseased, while medications are restricted to a
relatively small number of subjects; (iii) food products
have their nutritional proﬁle and form a part of the
global diet, adjusted to local nutrition recommendations;
(iv) the choice of a food product is made by the consumer
and therefore the choice is based on multifactorial decision
making being more random or inﬂuenced by habits,
preferences and perceived beneﬁts, unlike a medically pre-
scribed product; (v) some food products are only available
through specialised channels (e.g. food for special medical
purposes), but most of them are sold in shops and super-
markets without any advice except for advertising; (vi) as a
rule, food products are not subject to reimbursement by
social security or welfare programmes (although certain
refund experiences of speciﬁc products by health care
systems or insurance companies have been tried). The
link between the consumption of a food product and
future health status is more difﬁcult to establish than the
effect of a drug treatment. To match the above-mentioned
speciﬁcities of the health-enhancing food sector, the goal
would be to generate methodologies in order to correctly
predict the impact of food-related health effects and
health economic outcomes from a broader perspective.
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A workshop was organised to gather specialists from
different disciplines. The agenda of this expert workshop
was introduced by an overview of the basics in health
economics for the nutrition specialists and a presentation
of clinical issues related to nutrition for the health
economic and health outcomes research experts. The
panel discussion was guided by statements drafted from
existing guidelines for health economics
(5–9) to provide
the basis of establishing nutrition economics as a new dis-
cipline. A set of articles focusing on the economic aspects
of nutrition was provided to give the participants some
further background information
(10–18). For the subsequent
debate on the methodological issues, it was important to
determine what the term food or nutrition covers.
The following categories were distinguished: (i) conven-
tional food: all basic food in the daily diet; (ii) functional
food: similar in appearance to conventional food,
consumed as part of a usual diet and which has demon-
strated physiological beneﬁts and/or reduces risk of
chronic disease beyond basic nutrition; (iii) infant formula
and infant foods: food specially made for meeting the
nutritional requirements of infants during breastfeeding
period or children up to the age of 3 years; (iv) food for
special medical purposes
(19).
It was decided that the main focus of the discussions
would be on functional foods, partly for practical reasons
and because functional foods suggest a beneﬁcial effect
in the general population addressing a risk factor for
future morbidity. Study protocols for nutritional interven-
tion trials are designed according to the predeﬁned
beneﬁts and/or risks that can be inﬂuenced by functional
food as shown by measurable parameters. This also applies
to conventional food that has shown a beneﬁcial effect
(functionality) on a target population in a nutritional inter-
vention trial setting; dietary ﬁbre or fatty acids can be a
functional food, as well as products that have undergone
substitution of an ingredient, e.g. replacing saturated by
polyunsaturated fat, and that can play an important role
in health outcomes and possess economic sequelae.
Target groups of functional foods within the general
population can be identiﬁed as healthy or non-diseased
populations with risk factors or, to put differently,
diseased populations that have not been diagnosed yet.
The outcomes of existing nutritional intervention trials
provide a concrete framework as a starting point for
testing the potential relevance for conducting an economic
analysis. The specialists participating in the meeting
evaluated the issues that are relevant when exploring the
ﬁeld of nutrition economics, and the details of their
conclusions are presented below.
Target audience of nutrition economic studies
Clear overlap exists between pharmacoeconomics and
nutrition economics, and several aspects of these areas
are relevant to similar target audiences. However, one
distinguishing group is speciﬁc for pharmacoeconomics:
those who absorb or bear the costs – in health economics,
these are commonly referred to as the payers and represent
the entity that will be in charge of at least some of the
medical expenses for diseased people. This category
does not have its equivalent in nutrition economics.
Another differentiating feature is the reimbursement
of medical treatment v. an individual choice of food
purchase that consumers pay for themselves. The healthy
population without treatment also contributes in support-
ing the burden of the national health care expenses.
Nutrition economics will thus be relevant not only for the
health care providers and policymakers, but also for the
general public.
Physicians are another important target audience. The
physician or health professional will mostly be interested
in the clinical effectiveness rather than in the costs. In
addition, without any regulatory framework, a practitioner
may be reluctant to recommend directly to anyone the
use of a particular food product for health on the grounds
of personal liability. Recommendations or guidelines
endorsed by a scientiﬁc or professional society, regulatory
body or health care providing system are required; but at
this stage, evidence to support those recommendations is
for the most part lacking. There is a need for a trustworthy
source to guide health care professionals in applying
combined health and economic outcomes of nutrition in
their daily medical practice. Professional organisations
responsible for guidelines may therefore be another
target audience. For example, if there is a recommendation
from the American Heart Association, physicians will have
a solid ground to follow that guidance. Considering the
increasing pressure on health care budgets, physicians
may well be willing to provide nutritional advice that is
cost-effective or even that contributes to net cost-savings
(either immediate or in the future). In addition, a reduction
of their workload may be a result. Within hospitals, the
interest of health care providers is more oriented towards
budget impact data and data related to hospital stays
than towards cost-effectiveness data and even less towards
food-related cost-effectiveness. Employers may form
another target audience for nutrition economics because
of the potential to avoid future productivity losses. Data
on the impact of nutrition-related health conditions on
productivity losses, in terms of either absenteeism or pre-
senteeism
(12,20) (i.e. reduced productivity while at work
despite illness) are emerging.
Nutrition-related disorders cause an increasing need
for health care interventions and also may have a consider-
able impact on HRQoL, including physical functioning
and psycho-social well-being
(21). Therefore, the targets
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(e.g. National Institute for Clinical Excellence in the UK,
German Institute for Quality and Efﬁciency in Health
Care in Germany, College voor zorgverzekeringen in
the Netherlands, TLV (Dental and Pharmaceutical Beneﬁts
Agency) in Sweden, Health Technology Assessment
Agencies and Units members of International Network
of Agencies for Health Technology Assessment, European
network for Health Technology Assessment and EuroScan,
Health Technology Assessment International), central
public policymakers (e.g. National Health Service in the
UK and Haute Authorite ´ de Sante ´ in France), regional
public policymakers, third-party payers, care-providing
institutions (e.g. hospitals and nursing homes), health
care professionals, individual consumers, employers and
even food producers (e.g. food companies and farmers)
when planning investments for future development.
Conclusion. A reduction in the health and economic
burden achieved or avoided through food will be of interest
for many different stakeholders, including healthy individ-
uals who contribute in ﬁnancing the health care needs.
Perspective of nutrition economic analyses
In health economics, an economic evaluation is conducted
from a deﬁned perspective which determines the costs
and beneﬁts that are taken into account. It relates much
to the discussion on the target audience. In the ﬁeld of
nutrition policy, all costs and effects are important regard-
less who is paying for, or receiving, them, to ensure a
true societal perspective. Individual purchases of food pro-
ducts are made by consumers using their own money.
They will beneﬁt from well-conducted studies on beneﬁts,
but will judge value for money themselves through the
price and perceived beneﬁt. In this situation, the focus
shifts from cost-effectiveness towards willingness to pay.
Thus, the economics of nutrition can be much broader
or narrower than cost-effectiveness analysis as applied to
pharmaceuticals. In England and Wales, the National Insti-
tute for Clinical Excellence is already evaluating public
health programmes (for example, exercise-promoting pro-
grammes or tobacco-reduction programmes
(22) which are
much broader than product-related approaches) using a
cost perspective that includes the whole public sector
and not just health care. Agencies in other countries such
as Australia and Canada are also going down that particular
route. In the Netherlands and Germany, the general
taxpaying public is showing increasing interest in preven-
tive health care. One of the driving elements of health
policy at the moment is to persuade people to take respon-
sibility for their own health and achieve maximal beneﬁts
with the health system spending minimal money on it.
This puts the question of perspective in a context that
bridges the gap between the needs of the health care
system and the interests of the non-diseased individuals
who are bearing part of the costs, whether ﬁnancial or in
another way, and who have to be convinced of changing
their lifestyle
(23).
Different interesting scientiﬁc issues arise depending
on the adopted perspective. It comes back to the attribu-
tion of costs to different people. Nutrition economic
analyses may provide valuable evidence of food habits
likely to reduce part of the burden of health care. The
general public who already accept personal expenses for
their own well-being and ﬁtness might be more receptive
to positive messages rather than being warned constantly
on the dangers of fat, salt and sugar.
Conclusion. The perspective of nutrition economics
needs to be broader than that usually applied in cost-
effectiveness analysis in health care.
Outcome measurement
The measurement of health outcomes in nutrition depends
on the user group and is related to the speciﬁc nature
of food as well as to speciﬁc aspects concerning preven-
tive treatment in sub-healthy consumers. This leads to
additional methodological issues. It is not easy to achieve
measurements of the global effects of food habits within
the general population. There is a problem of proof
related to the choice of endpoints that is difﬁcult to
handle. Some interventions have more immediate effects
than others. Hence, a couple of questions arise: How to
measure the preventive effect, if it is produced several
years later?
(24–26) What will be the right moment to start
monitoring? Will it be possible to work with health,
rather than with disease markers, and if so what would
be their nature? For example, in osteoporosis, bone density
is a sensitive surrogate marker, but this does not easily
permit the demonstration of the superiority of a speciﬁc
diet (in a nutritional intervention trial) on the target popu-
lation of seniors. The most convincing evidence would
come from studying 25 year olds, or even children over
time and relating the intakes early on to their bone
health observed later in life. However, the effects seen
would not only be associated to aspects of the diet like
the Ca level but also to a multitude of other factors that
would need to be considered. This would take much
time and ﬁnancial resource. The food industry potentially
has not enough resources to engage in such programmes
and it will not be a priority for policymakers who are
more likely to focus on expensive treatment regimens to
induce a rapid budget impact. Which pathway can we
expect for the methodological approach in the ﬁeld of
nutrition economics? There is a three-point continuum
on which this can be based: efﬁcacy, effectiveness and
efficiency (Fig. 1). Efﬁcacy is concerned with answering
the question ‘does it work?’ in a clinical trial setting. Effec-
tiveness refers to ‘does it work under real daily life
circumstances?’ and efﬁciency adds cost considerations
to the latter by asking ‘is it worth it?’ Along this con-
tinuum, the evaluation of nutrition-related health beneﬁts
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way. Adapted study designs will be needed and may
include observational, experimental and pragmatic trials
using registries. A registry is an observational study,
having a much larger sample size than a randomised
controlled trial (RCT) and more comprehensive data
collection
(27). People are followed prospectively and data
are collected on clinical outcomes reported by clinicians,
as well as on resource use, functional status and HRQoL
as reported by the subject. Observational studies are fully
naturalistic and they have, in spite of concerns on internal
validity, a high external validity. The use of a registry suits
perfectly with the concept of evidence-based medicine,
which means that clinical encounters should be supported
by scientiﬁc conclusions based on sound data as much
as possible. The large size of a registry is appropriate for
health economic evaluation in food and, although the
effort should not be underestimated, allows the develop-
ment of statistically solid multiple regression equations
for adjustment of confounding variables, which can be
incorporated in a health economic model. Furthermore,
an improvement of information systems in health care
would make large-scale and long-term studies more
feasible at a reasonable cost and although people are
very slow to pick this up, this is gradually starting to
happen
(28). Long-term outcomes are usually not interesting
for payers, but they are relevant in health economic ana-
lyses from the societal perspective. It now becomes poss-
ible to do pragmatic trials with automated data collection
through linked primary and secondary care data systems.
Conclusion. Outcome measures are similar to those
considered in preventive interventions and protocols
should include observational and experimental designs
depending on the nature of the outcome to be measured.
Cost-effectiveness analyses
Economic evaluations express the relation between a
measured beneﬁt and the cost of the intervention that is
needed to obtain this beneﬁt. In a medical setting, the
cost items that are directly associated to the intervention
are more or less easy to determine; indirect cost and
long-term costs consequences of a chronic disease state
or of its avoidance are more difﬁcult to include and will
often be based on estimations. In medicine, the most
obvious beneﬁt will be cure, but many other possibilities
exist, such as effects on morbidity (e.g. reduced stroke
rate and higher response rates). In the ﬁeld of nutrition,
there can be a variety of measurable health beneﬁts
such as a decrease of symptoms, a risk reduction or
health maintenance, a delayed onset of disease develop-
ment and even increased longevity. The identiﬁed health
gain needs to be quantiﬁed or valued in order to establish
the impact of a given intervention or programme on
the health status of the concerned target population. In
health economics, this value is commonly derived from
the HRQoL and expressed in quality-adjusted life years
(QALY). Today, one of the most commonly used ﬁnal out-
comes of a cost-effectiveness analysis is being calculated
as the additional costs per QALY gained. However, one
may question whether the QALY is perfectly suitable to
capture the outcomes of nutrition.
The methods of economic analysis routinely used in
the pharmaceutical sector were developed from academic
studies in the 1960s and 1970s. The methods were used
by policymakers in national health systems, such as the
National Health Service in the UK, and in the 1980s, the
pharmaceutical industry began to use cost-effectiveness
analysis to communicate the beneﬁts of their products
(29).
The most rapid increase in the use of cost-effectiveness
analysis came when it became a requirement of the
reimbursement authorities in many countries, beginning
with Australia in 1992.
Although in some countries the reimbursement
agencies work with an explicit cost per QALY threshold
as an aid in decision making, many other countries are
reluctant to use an explicit cost-effectiveness threshold.
So far, the food industry does in general not include
items on cost and utility data in their nutritional interven-
tion trials, mostly designed to demonstrate a cause–effect
relationship. HRQoL from the subject’s direct viewpoint is
a relevant criterion. The main difﬁculty lies in assessing
the changes in quality of life in a (sub) healthy person,
looking for protection against a long-term disease risk.
Nutrition-related risk reduction is often an add-on to a
normal lifestyle in healthy persons with a potential health
problem. In other cases, there can be signiﬁcant quality
of life beneﬁts in a relatively short period of time; for
example, when obese people start to realise that they
can do things they could not do before, beginning to feel
better about themselves and becoming less sedentary. So,
Biological
effect
Experimental
proof
Demonstration on
target group in
real-life setting
Public
health
Efficacy Effectiveness
Efficiency
Societal perspective
Fig. 1. Three-point continuum of nutrition economics.
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problem, HRQoL impact might be easier to appraise,
depending on the availability of validated nutrition-speciﬁc
measurement instruments. In any case, speciﬁc ways of
measuring HRQoL in sub-healthy people are needed.
It will be necessary to identify, measure and value in
some detail the impact of an intervention on the subject’s
functioning and well-being.
A frequently used approach to adapt cost-effectiveness
from a trial to a real-life situation is modelling. Modelling
studies may also provide the necessary cost-effectiveness
information using various existing data sources for clinical
and economic information. Modelling studies are based on
decision analysis, which is a well-recognised method for
analysing the consequences of decisions that are made
under uncertainty
(30). Projections about food’s effective-
ness and expected costs can be modelled using realistic
and explicit assumptions based on data from clinical
studies. In addition, modelling often helps overcome the
practical limitations of prospective studies, particularly for
preventive programmes that may require longer-term
extrapolations of health effects and cost implications. If
diet is considered as a key component of health, it might
be worthwhile to see if nutrition plays an enabling or hin-
dering role in adopting or in reinforcing a healthy lifestyle.
Conclusion. For determining beneﬁts in nutrition econ-
omics, the appropriateness of the available quality of life
questionnaires for answering the research question at
hand should be checked. Development of nutrition-
speciﬁc measurement instruments suited to the complexity
of the ﬁeld might be needed.
Comparisons in nutrition economic assessment
In health economics, the use of comparators is mandatory
and often a comparison is made with ‘standard care’ or
‘usual care’. A placebo is only to be used when no better
alternative is available. The pharmaceutical trial world
has moved on from true placebo control to active treatment
comparators, due to ethical issues. In nutrition studies, the
results are very much dependent on how the placebo or
comparator has been designed. This is nicely illustrated
when looking at lactose intolerance: whatever you chose
as a placebo, a subjective overestimation of the frequency
of milk intolerance may considerably affect the study out-
comes
(31–34). The key question then is what is the best
comparator? Should a probiotic yoghurt be compared to
a placebo yoghurt? What is a placebo yoghurt? Is it an acid-
iﬁed milk product without bacteria or is it fermented milk
with or without active starter cultures or active metabolites?
If the study design implies that the control group will have
to consume a product that is not part of their daily diet, this
induces an interference that might invalidate the outcomes
of the experiment. Depending on what you want to inves-
tigate, no intervention can also be an acceptable compara-
tor. Linked to the need for identifying the right comparator,
it might be important to identify upfront what is the unmet
need and what might be the real outcomes on health.
There are not many nutrition studies that have actually
compared competing products; if a new dairy product is
added to the diet, people will not eat it on top of their
usual quantity of food, and they might stop eating some
other food product. It has to be deﬁned how such changes
in diet can be taken into account in the evaluation.
Conclusion. Comparisons should be carefully deﬁned
and controlled; design and analysis are important issues
to address.
Time horizon
Health maintenance, health improvement and disease
risk reduction are among the most important beneﬁts of
nutrition in the sub-healthy population. There are usually
no short-term measurable beneﬁts and beneﬁts will not
immediately show cost savings and gains in QALY. In
chronic conditions, delayed onset of disease and second-
ary prevention constitute valuable information that can
be modelled when valid data are available. This refers to
the earlier discussion about evidence-based medicine
and science driving the whole continuum. Many RCT do
make it clear what the eventual long-term effects are. In
all cases, it is important to have a clear sight on positive
effects as well as on the negative ones that should be mon-
itored and reported. Some effects that can be evidenced by
identiﬁed markers on a shorter term can already be linked
to long-term outcomes. An example is evidence of the
clinical beneﬁt of the phytosterols, where the reduction
of LDL-cholesterol is linked to a reduction in long-term
clinical events, which is generally accepted in the medical
community. A future impact may offer an appealing
argument for health policymakers and it can be one of
the factors for nutrition economic modelling. For nutrition
evaluation, the time horizon is by deﬁnition long term and
although it seems attractive to use the QALY as an outcome
measure, this technique may not be perfectly suited in its
present form to measure the outcomes of food products.
Of note, in the care sector, there are also discussions
going on presently relating to the question of whether
the QALY can be used as a sufﬁciently comprehensive
measure of beneﬁt
(35). One of the challenges for the ﬁeld
of nutrition economics will be to develop methodologies
adapted to the complexity of nutritional research and
the interactions between diet, lifestyle and multiple other
factors. It should be kept in mind that measurement of
the long-term impact of diet and food habits will be
relevant for all nutrition-related disorders, whether it
occurs through reducing risk factors or is due to improve-
ment of under-nutrition or overeating.
Conclusion. There is a challenge to develop method-
ologies adapted to the complexity of nutritional research
and the interactions between diet, lifestyle and multiple
other factors. Modelling potentially plays a very prominent
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will take long time spans to develop.
Identiﬁcation of costs
Looking at the impact of nutrition beneﬁts on the public
sector budget is timely and it will need to be broadened
out in order to address it from a true societal perspective.
This means that all related costs and involved resources
should be quantiﬁed, no matter who pays for them.
Typically, in economic evaluations of health care interven-
tions, a distinction is made between direct and indirect
costs, and between costs incurred inside and outside the
health care sector
(36). These data may be collected through
several sources and, depending on the study population
and the health condition concerned, the cost categories
that may be important include prescription and over-the-
counter medications, consultations with the general
practitioner, visits to the outpatient department, out-of-
pocket costs for alternative ‘therapies’, costs of productivity
losses, cost of informal care giving, savings associated with
delayed entry into a residential home and cost of accompa-
nying services looking after children or the elderly. In the
case of a health beneﬁt induced by a functional food
product, the price difference of this product as compared
with the traditional food item has to be taken into account
when conducting an economic evaluation. Thus, there is a
complexity in identifying the costs due to the huge number
of variables that may enter in the analysis and by the way
in which they will be quantiﬁed.
Conclusion. The costs to be taken into account should
consist of not only direct but also indirect costs in order to
produce a comprehensive picture of the resources involved.
Discounting
In health economic analyses, the principle of discounting
is important. It aims to translate the value of future costs
and health effects in today’s rate. This is done because
costs and effects may occur at different points in time
and people have a so-called positive time preference,
which means that they like to have pleasant things as
soon as possible, rather than in the uncertain future,
while they would rather postpone unpleasant things and
costs. A high discount rate or a far ahead beneﬁt will
lead to a lower present value of the analysis results. There-
fore, discounting is in general not in favour of preventive
programmes, as for example vaccination
(37,38). Experi-
ments seem to indicate, as would be expected, that if
you offer individuals a set of options, some of which
include themselves sharing in the beneﬁt and some do
not, the discount rates obtained in the former are much
lower than the discount rates in the latter
(39,40). People
are concerned with the balance of their own beneﬁts
over their lifetime and this is what conditions their
willingness to pay. Can there be an argument in nutrition
assessment technologies of using discounting rates that
are different from the rates that are commonly used for
pharmaceutical cost-effectiveness analyses? In the long-
term context, one should be aware that due to discounting,
the future cost savings and gain in QALY can be reduced
substantially. Considering a different discount for preven-
tive programmes will not be accepted by the health
economic community, because it is in conﬂict with general
economic principles of valuing the future beneﬁts.
Conclusion. It is too early to establish a recommen-
dation about discounting in relation to the long-term
impact of nutritional health effects.
Internal and external validity
How should generalisability of results in a nutrition
economic analysis be evaluated? Internal and external
validities have to be addressed separately. Internal validity
is the extent to which the analytic inference derived from
the study sample is correct for the target population. Exter-
nal validity is the extent to which the economic analysis
performed in the study sample is also true in the external
population.
The assessment of nutrition beneﬁts was discussed in
detail, and the group expressed the following viewpoint
on the quality of the evidence on efﬁcacy. On the one
hand, RCT have a high internal validity and are considered
the gold standard for proving a functional beneﬁt, as well
as the cause–effect relationship. However, data from
RCT do have in general a low external validity because
they have strict inclusion and exclusion criteria and treat-
ments are protocol driven
(41), leading to overestimation
of units of health care utilisation. Although randomisation
is usually applied to balance the confounding variables,
inclusion criteria of patients and selection of investigators
are fairly rigid. Of course, health economic data (effective-
ness and resource utilisation) may be collected alongside a
RCT
(42–45). However, this is not always ethical or feasible.
For example, in a comparison of nutrition with drugs,
randomisation can be performed, but adequate blinding
will be complex or even impossible in some cases.
For external validity, when it comes to nutrition econ-
omics, the design has to reﬂect the real-world setting and
pragmatic trials will allow avoiding or reducing the
problem of missing evidence. Depending on the type of
food and its beneﬁcial effect, it is acceptable for the
health economic experts to require the highest possible
evidence. For example, observational studies may provide
adequate evidence, depending on the endpoint. Experi-
mental trials are seldom performed for a public health
intervention, because people would be in part extracted
from the conditions where the intervention is going to be
used afterwards. Even in RCT, the biomarkers are not
always tied to diseases in ways that are meaningful. Of
course, this raises the question of the quality of trials.
In the pharmaceutical world, there is a perception that
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the case; it is possible to conduct a pragmatic trial with
good design principles, leading to adequate levels of
evidence. For example, the ﬁrst guidelines for CVD
management were based on the Framingham Study
(46).
The conclusions come from a series of cohort studies
and still remain part of the evidence that now relies on a
mixture of observational and interventional data. So,
pragmatic trial that is well done is not bad evidence,
rather it is evidence of a different type.
Conclusion. Causal relationships have to be demon-
strated in randomised clinical trials but complementary
informative data collection from the real-life setting is
needed for health economic decision making.
Dealing with uncertainty
The two blocks of traditional uncertainty to standard
health economic evaluations are ﬁrst of all associated to
the fact that the missing link between short-term surrogate
endpoints and the long-term hard outcome is usually not
established through a RCT, but can be based on observa-
tional cohort studies or case–control studies. Since the
real-life setting in nutrition economics increases the
number of confounding factors, more extensive sensitivity
analyses will be required. Secondly, uncertainty is more
than only variance in a distribution of input parameters
and is also related to the choice and type of data sources
used in the extrapolation. The issue of uncertainty can be
further managed through scenario analyses based on the
modiﬁcation of the underlying assumptions or data sources
of the model. Other studies can subsequently be used to
validate the outcomes of the model. There are many inter-
actions between variables, which indicates that nothing
short of a probabilistic sensitivity analysis would be ade-
quate, because it is not possible to change one variable
at a time without having modiﬁed several of the others.
In some cases, it will be possible to have very clean trial
designs, for example when adding an antioxidant to
juice, but the majority of the questions are more
complicated. If you want to change the level of a particular
variable, it will presumably have a knock-on effect on
many other factors. One could take the extreme example
of elderly people in a nursing home, quite often suffering
from constipation. If you intervene against constipation, it
will actually improve appetite. The increased food intake
increases their well-being and activity level and then
many more elements have been modiﬁed than just the
one product that has been given initially. This difﬁculty
even holds when considering the balance between beneﬁt
and risk. This can easily be illustrated by the following
examples. Acetaldehyde is classiﬁed as a carcinogen. But
it is also normally present in fruit, vegetables, yogurt and
in infant foods, and is a common metabolic intermediate
product in human physiology. In many food products,
the presence of acetaldehyde seems to be associated
with other protective components which may counteract
its detrimental effects. However, in alcohol products, it
can rapidly lead to problems. What is the best way to
take this into account when conducting nutrition interven-
tion studies and how should the information obtained
be translated to both the public and health professionals
as well as to regulatory bodies? We know that sulphites
in red wine are harmful to health. But again, moderate
wine consumption or other alcohol-containing drinks is
also associated with some health beneﬁts
(47); and people
will also factor in their own personal taste, the pleasure
they get from the substances they appreciate when eating
or drinking them. Will there ever be a way to produce
any transparent quantitative analysis for the beneﬁts
and risks, the real balance between the negative and the
positive? The right people to make a decision would be
those subjects themselves, who are taking the risks and
getting the beneﬁts. But this requires awareness and under-
standing of the available information. A way to get over
this problem is the use of consumer-based self-reported
outcomes, which are based on full knowledge of the
intake and the use of validated HRQoL measures, with
standardised administration guidelines to minimise the
measurement error.
Conclusion. Uncertainty will be one of the big
challenges in the ﬁeld of nutrition economics.
Conclusion
Taken together, it appears important to deﬁne the new
area of ‘nutrition economics’ carefully as the discipline
dedicated to researching and characterising health and
economic outcomes in nutrition for the beneﬁt of society.
Early involvement of all relevant parties in deﬁning the
principles, proof of concept and the link between evi-
dence-based medicine and nutrition economics will be
mandatory for managing the complexity and for warrant-
ing a solid foundation in developing this new ﬁeld. In gen-
eral, prevention and public intervention programmes carry
an upfront cost before potentially bringing the health care
expenses down. The question is whether the health ben-
eﬁts are large enough to justify the additional costs regard-
less of who has to pay for them. The nutrition economics
approach aims at answering this question through outcome
measurements that reach speciﬁc quality objectives. It
will be important to conduct economic analyses for the
different target audiences, to put costs in perspective, to
calculate cost savings and health beneﬁts and to quantify
them in a manner that takes into account the complexity
of the question. The speciﬁc outcomes of interest should
be assessed in a real-life routine situation, not in a con-
trolled experiment, as is the case for preventive measures
and programmes. In the case of cost impacts from nutri-
tional beneﬁts, the possibility of a dominant result in
terms of net cost-savings cannot be excluded and a speciﬁc
nutrition economic model certainly will be useful to obtain
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a multidisciplinary approach to nutrition and economics
will be essential for generating the required information
that spans the whole cycle. Also, food companies may
play a decisive role in their ability to inﬂuence the pen-
etration rate of cost-effective health-enhancing products.
On a European level, there are several interesting pro-
grammes demonstrating how to involve decision makers
in comparable multi-disciplinary processes. A forum such
as created by Health Technology Assessment specialists,
including decision makers, scientists, regulators, industry
and international organisations, driven by nutritional scien-
tists, would have the potential to be quite productive and
facilitate the implementation of nutrition economics as a
kind of policy platform. Examples of similar approaches
can be found in the recently established ‘Policy Forum’
by Health Technology Assessment International (http://
www.htai.org). There are a number of allied disciplines
from which knowledge and modelling experience can be
drawn for developing and improving our knowledge in
the ﬁeld of nutrition economics. To better comprehend
nutritional sequelae, the group of experts participating in
this workshop suggest initiating an interest group bringing
together nutrition researchers and specialists interested in
policy to become engaged as an independent entity on
establishing an economic agenda, in addition to a scientiﬁc
research agenda.
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